Datavault AI seeks 19.9% of DataMEDS in exchange for a license: health data, the contested asset

By TBBW (Tampa Bay Business and Wealth) · October 22, 2026.

Philadelphia-based AI company Datavault AI is seeking a 19.9% stake in DataMEDS AI, a Tampa healthcare company, in exchange for expanding the technology license it already grants it. Both are publicly traded and announced a non-binding letter of intent on Thursday, October 22, according to TBBW.

The deal would give Datavault AI three things: that 19.9% on a fully diluted basis (that is, counting all shares that could exist, not just current ones), royalties on the commercialization of the licensed technology and a board seat at DataMEDS. Datavault would retain the intellectual property, and DataMEDS would bear the cost of bringing the technology to market. According to published reports, Datavault would not contribute cash.

Neither company has disclosed the financial value of the transaction. The royalty terms and exactly which patents the expanded license would cover have not been finalized either. And with no definitive agreements signed, both parties can walk away. Datavault CEO Nathaniel Bradley says much of the due diligence (the review of the company) and document preparation has already been completed under an earlier letter, and that a closing in the fourth quarter of 2026 is realistic. That is his claim, not a done deal.

The relationship already exists: DataMEDS licenses Datavault technology for its PharmacyChain and EinsteinRx platforms. The expansion would add capabilities for patients to control access to their medical information and to manage, value and monetize health data generated by pharmacies, labs, wearables and other services. DataMEDS, formerly Wellgistics Health and listed on Nasdaq, operates pharmacies, pharmaceutical distribution and health technology. It includes subsidiary Corexa Health and diagnostics lab Helomics, which develops tests to guide oncologists in chemotherapy decisions.

**Our take.** What stands out is not the percentage but the verb: "monetize" health data. There is a thesis here worth splitting in two. On one hand, letting patients control who accesses their records is real progress. Well-governed, shareable data is the raw material of the medicine that, in the long run, could bring us closer to eradicating diseases: earlier diagnoses, personalized treatments, faster trials. On the other, "value and monetize" raises the question of who gets paid. If the business model aligns with patient well-being, fine. If it aligns with retaining and selling information, the promised control may end up as nothing more than a consent form.

The headline also deserves toning down. This is a non-binding letter, with no price, no defined patents, between two listed companies. In general, paying with licenses and shares instead of cash is common when one party has little capital, and it calls for caution in reading the real value of what is being exchanged. As industry context, such arrangements are often presented as strategic alliances, and what validates them is whether they reach product and revenue, not the announcement.

What to watch: whether definitive agreements are signed before year-end, which patents are actually included and, above all, what concrete rights patients will have over their data and how much of the value generated flows back to them. That fine print will show whether this is useful infrastructure for the medicine of the future or just a new way of putting a price on our medical history.